Edition:
India

Titan Pharmaceuticals Inc (TTNP.OQ)

TTNP.OQ on NASDAQ Stock Exchange Capital Market

0.95USD
20 Apr 2018
Change (% chg)

-- (--)
Prev Close
$0.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
16,901
52-wk High
$3.10
52-wk Low
$0.95

Select another date:

Mon, Apr 2 2018

BRIEF-Titan Pharmaceuticals Q4 Loss Per Share $0.17

* TITAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Titan Pharmaceuticals Executes Agreement For Acquisition By Molteni Of Probuphine In Europe And Other Territories

* TITAN EXECUTES AGREEMENT FOR ACQUISITION BY MOLTENI OF PROBUPHINE® IN EUROPE AND OTHER SELECT TERRITORIES

BRIEF-Titan Announces Amendment To Horizon Loan Agreement

* TITAN PHARMACEUTICALS INC - ENTRY INTO AN AMENDMENT TO JULY 2017 LOAN AGREEMENT WITH HORIZON TECHNOLOGY FINANCE CORPORATION

BRIEF-Titan Pharmaceuticals Says Co​ Entered Into A Binding Term Sheet With L. Molteni & C. Dei F.Lli Alitti Societ*I Esercizio

* TITAN PHARMACEUTICALS INC - ON NOV 27, CO​ ENTERED INTO A BINDING TERM SHEET WITH L. MOLTENI & C. DEI F.LLI ALITTI SOCIET*I ESERCIZIO - SEC FILING

BRIEF-Titan Pharmaceuticals Partners With Molteni To Market Probuphine In Europe

* TITAN PHARMACEUTICALS PARTNERS WITH MOLTENI TO MARKET PROBUPHINE® IN EUROPE

CORRECTED-BRIEF-European Medicines Agency Accepts Titan's Marketing Application For Probuphine

* EUROPEAN MEDICINES AGENCY ACCEPTS TITAN PHARMACEUTICALS' MARKETING AUTHORIZATION APPLICATION FOR PROBUPHINE®

BRIEF-Titan Pharmaceuticals reports Q3 loss per share of $0.20

* Titan pharmaceuticals reports third quarter 2017 financial results

BRIEF-Titan Pharmaceuticals files for offering of up to 280,612 shares by selling stockholder

* Titan Pharmaceuticals Inc files for offering of up to 280,612 shares of co's common stock by the selling stockholder - SEC filing‍​ Source text:[http://bit.ly/2izOUEZ] Further company coverage:

Select another date: